ArticleHuman gene therapy2009
Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media.
Article in Human gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Ablation of prostaglandin ENature biomedical engineering · 2026Article
- Baboon endogenous retrovirus (ERV) envelope pseudotyped lentiviral vectors outperform human ERV lentivectors for transduction of T, B, NK and HSPCs.Gene therapy · 2026Article
- CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency.Nature cancer · 2026Article
- High-titer human packaging cells producing γ-retroviral vectors pseudotyped with engineered baboon endogenous retrovirus (BaEV) envelope proteins.Frontiers in molecular medicine · 2026Article
- Modeling immunotherapies in live 3D human cancer tissue bioreactors.Theranostics · 2026Article
- The resting and ligand-bound states of the membrane-embedded human T-cell receptor-CD3 complex.Nature communications · 2025Article
- Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors.Cancer immunology research · 2025Article
- Leucine Zipper-based Cell Sorting for Purification of Dual-vector-transduced Cells.Journal of visualized experiments : JoVE · 2025Article
- Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function.bioRxiv : the preprint server for biology · 2025Article
- A convenient viral transduction based method for advanced multi-engineering of primary human (CAR) T-cells.Journal, genetic engineering & biotechnology · 2024Article
- Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies.Cell stem cell · 2024Article
- Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells.Gene therapy · 2024Article
- Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.Cancer immunology, immunotherapy : CII · 2024Article
- Mutation-specific CAR T cells as precision therapy for IGLV3-21Nature communications · 2024Article
- Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.Nature biotechnology · 2023Article
- Article
- Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.Journal for immunotherapy of cancer · 2023Article
- Efficient clinical-grade γ-retroviral vector purification by high-speed centrifugation for CAR T cell manufacturing.Molecular therapy. Methods & clinical development · 2023Article
- Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.Journal for immunotherapy of cancer · 2023Article
- PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models.Cellular oncology (Dordrecht, Netherlands) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Retroviral vectors derived from the Moloney murine leukemia virus have been used in successful and promising gene therapy clinical trials. However, platforms for their large-scale production must be further developed. As a proof of principle, we reported the generation of a packaging cell line that produces amphotropic retroviral vectors in suspension and serum-free medium (SFM). In the present study, we have constructed and characterized two retroviral packaging cell lines designed for gene transfer in hematopoietic cells. These cell lines grow in suspension and SFM, and produce high-titer RD114- and gibbon ape leukemia virus (GALV)-pseudotyped vectors for a 3-month culture period. Viral particles released are as robust during repeated freeze-thaw cycles and on thermal inactivation at 37 degrees C as their counterparts produced in cells cultured adherently with serum. We also show that RD114- and GALV-pseudotyped vectors produced in suspension and SFM efficiently transduce human lymphocytes and hematopoietic stem cells. As these retroviral packaging cell lines distinctively maintain high vector titers while growing in suspension and SFM, we conclude that these cell lines are uniquely suitable for large-scale clinical-grade vector production for late-phase clinical trials involving gene transfer into hematopoietic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.